Obstructive Sleep Apnea of AdultSleep
What this study is
Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.
Study details
- Sponsor
- Mayo Clinic
- Conditions
- Obstructive Sleep Apnea of Adult
- Enrolling
- 120 people
- Starts
- 2018-01-08
- Est. completion
- 2029-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 60 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- BMI ≤40 kg/m2
- Not a current smoker or tobacco user
- Individuals with treated hypertension, prehypertension, and dyslipidemia will be allowed to participate in the study
- On no prescription medications other than those medications used to treat asthma, seasonal or environmental allergies (such as Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), depression, acid reflux (such as antacids or proton pump inhibitors), topical skin treatment medications or shampoos, contraceptive pills, or intrauterine devices. Other medications may be allowed at the discretion of the study staff.
- Not pregnant or breast feeding and not intending to become pregnant or breast feed
- Ability to provide written informed consent
- If a subject is on aspirin or any other anti-inflammatory medication but free of known vascular disease and depending on the indication, the study doctor may ask the subject to suspend aspirin or anti-inflammatory therapy for 7 days prior to participation in the study. In the event that the subject does not stop the aspirin or other anti-inflammatory medication, they will not be able to participate in the study because of the risk of bleeding during the fat biopsy.
You can't join if
- Vulnerable study population will be excluded
- Presence of chronic kidney disease (creatinine >2.5 mg/dL) and/or active cancers
- Pregnancy
- Anemic (hemoglobin <12 g/dL for men and <11 g/dL for women)
- Smoking
- Use of chronic medications (statins, anti-inflammatory drugs, angiotensin II receptor blockers (ARBs) and/or angiotensin-converting enzyme (ACE) inhibitors)
- Blood or plasma donation during the past 2 months
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openMayo Clinic
Rochester, Minnesota, United States
- Somers_CPL LAB · Contact507-255-8794CPLOSA@mayo.edu
- Virend Somers, MD, Ph.D · Contact507-255-1144somers.virend@mayo.edu
Recruiting
Study team
Sponsor
Mayo Clinic
Study ID 17-003825
Principal investigator
Virend Somers, MD., Ph.D
Mayo Clinic
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.